{
    "paper_id": "PMC7228270",
    "metadata": {
        "title": "Clinical, immunological features and follow up of 20 patients with dedicator of cytokinesis 8 (DOCK8) deficiency",
        "authors": [
            {
                "first": "Sule",
                "middle": [],
                "last": "Haskologlu",
                "suffix": "",
                "email": "sulehaskologlu@gmail.com",
                "affiliation": {}
            },
            {
                "first": "Sevgi",
                "middle": [],
                "last": "Kostel Bal",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Candan",
                "middle": [],
                "last": "Islamoglu",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Caner",
                "middle": [],
                "last": "Aytekin",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Sukru",
                "middle": [],
                "last": "Guner",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Selin",
                "middle": [],
                "last": "Sevinc",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Sevgi",
                "middle": [],
                "last": "Keles",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Tanil",
                "middle": [],
                "last": "Kendirli",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Serdar",
                "middle": [],
                "last": "Ceylaner",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Figen",
                "middle": [],
                "last": "Dogu",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Aydan",
                "middle": [],
                "last": "Ikinciogullari",
                "suffix": "",
                "email": null,
                "affiliation": {}
            },
            {
                "first": "Alexandra",
                "middle": [],
                "last": "Santos",
                "suffix": "",
                "email": null,
                "affiliation": {}
            }
        ]
    },
    "body_text": [
        {
            "text": "DOCK8 deficiency is an autosomal recessive CID syndrome characterized by atopy (dermatitis, food allergies, and asthma), recurrent sinopulmonary and severe/persistent cutaneous viral infections, mucocutaneous candidiasis, early\u2010onset malignancy, and elevated IgE levels and eosinophilia.\n1, 2, 3 DOCK8 protein is a member of the DOCK180\u2010related family, which is involved in the cytoskeletal rearrangements. DOCK8 is required for T lymphocyte, natural killer (NK) cell function and survival, dendritic cell migration, B\u2010cell proliferation, immunoglobulin production, and antiviral cytokine production.4, 5, 6, 7\n",
            "cite_spans": [],
            "section": "INTRODUCTION",
            "ref_spans": []
        },
        {
            "text": "Atopic dermatitis (AD), food allergy (FA), and wheezing are usually the initial symptoms of DOCK8 deficiency during the early infancy period. However, chronic or severe infections, autoimmunity, and cancer development may affect the course of the disease and survival.8, 9 HSCT is the lifesaving therapy in DOCK8\u2010deficient patients; it should be performed as early as possible, before the occurrence of malignancies and fatal infections. HSCT has been shown to cure nearly all clinical and laboratory manifestations of DOCK8 deficiency by reconstituting the normal function of the immune system.10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22\n",
            "cite_spans": [],
            "section": "INTRODUCTION",
            "ref_spans": []
        },
        {
            "text": "Since the parental consanguinity rate is high (23.2%) in Turkey, DOCK8 deficiency has an important place among CIDs. Here, we retrospectively evaluated the clinical and immunologic features and treatment modalities of 20 patients with DOCK8 deficiency and follow\u2010up results of hematopoietic stem cell transplant (HSCT) in 11 patients among them as a single\u2010center experience.",
            "cite_spans": [],
            "section": "INTRODUCTION",
            "ref_spans": []
        },
        {
            "text": "Twenty patients (11 girls and 9 boys) from 14 families diagnosed and followed up with DOCK8 deficiency from 2004 to 2018 in Ankara University School of Medicine, Department of Pediatric Immunology\u2010Allergy of Children's Hospital, were evaluated retrospectively. DOCK8 protein expression was evaluated by flow cytometry as previously described.23 Next\u2010generation sequencing (NGS) and then Sanger's sequencing methods were used to detect and validate the DOCK8 mutations, respectively. The study was approved by the local ethics committee of Ankara University Faculty of Medicine and performed in accordance with the principles of the Declaration of Helsinki. The written informed consent was obtained from all the patients and/or their parents.",
            "cite_spans": [],
            "section": "Patients ::: MATERIALS AND METHODS",
            "ref_spans": []
        },
        {
            "text": "Eleven of /20 patients (six girls and five boys) are transplanted so far. The median time from diagnosis to HSCT was 8 months (0\u201048 months).",
            "cite_spans": [],
            "section": "HSCT characteristics ::: MATERIALS AND METHODS",
            "ref_spans": []
        },
        {
            "text": "Myeloablative conditioning (MAC) regimen consisting of IV fludarabine 40 mg/m2/day and IV busulfan 4 mg/kg/day on days \u22125, \u22124, \u22123, and \u22122 was administered to two patients (P5 and P7), while all others received treosulfan\u2010based reduced\u2010intensity conditioning (RIC). Treosulfan was given at a dose of 42 or 36 g/m2 (<1 year of age) in three divided doses on \u22127, \u22126, and \u22125 days. CsA was given alone in six patients transplanted from MRD and in combination with mycophenolate mofetil (MMF) or methotrexate (MTX) in two patients where peripheral blood\u2010derived stem cells (PBSCs) were used. One patient received tacrolimus and MTX. Antithymocyte globulin (ATG) was added to the conditioning regimen in a MUD (9 of 10 HLA matched) and a haploidentical (in conjunction with post\u2010transplantation cyclophosphamide (PT/Cy) for GvHD prophylaxis) donor setting. Acute and chronic GvHDs were graded according to modified Glucksberg and NIH consensus criteria, respectively.24, 25 Immunosuppression was stopped at 6 months after HSCT if there was no evidence of cGvHD.",
            "cite_spans": [],
            "section": "HSCT characteristics ::: MATERIALS AND METHODS",
            "ref_spans": []
        },
        {
            "text": "Myeloid engraftment was defined as the absolute neutrophil count being higher than 0.5 \u00d7 109/L and platelet counts exceeding 50 \u00d7 109/L without transfusion for at least three consecutive days. Immune reconstitution was evaluated by measuring the levels of CD3+, CD4+, CD8+, CD19+, CD20+, CD16+ 56+, CD4+ CD45RA+, and CD45RA+ CD31 (recent thymic emigrant, RTE) cells with flow cytometry (Beckman Coulter, Navios Software, Kaluza, Miami, USA). DOCK8 protein expression was analyzed with flow cytometry before and after 6 months following HSCT as described previously23 (Figure 1).",
            "cite_spans": [],
            "section": "Engraftment ::: MATERIALS AND METHODS",
            "ref_spans": [
                {
                    "start": 575,
                    "end": 576,
                    "mention": "1",
                    "ref_id": "FIGREF0"
                }
            ]
        },
        {
            "text": "Myeloid and T\u2010cell donor chimerisms were measured by using PCR\u2010based amplification of short tandem repeat sequences in DNA of the cells following the separation of peripheral blood samples at +1st, 2nd, 3rd, 6th, 9th, 12th, and 18th months following HSCT by Automated Magnetic Cell Sorting (Miltenyi Biotec). Full donor chimerism was defined when >95% of the cells originated from the donor. All patients were nursed in an isolated room, and they all received weekly prophylactic, antimicrobial, and IVIG therapies.",
            "cite_spans": [],
            "section": "Chimerism analysis ::: MATERIALS AND METHODS",
            "ref_spans": []
        },
        {
            "text": "The clinical characteristics, genetic features, and treatment modalities of the patients are presented in Table 1. The immunologic data are given in Figure 2. All patients were born to consanguineous parents. The median age at diagnosis and at HSCT was 3 years (range: 2 month\u201014 years) and 6 years (range: 2 months\u201015 years), respectively. Atopic dermatitis (18/20), recurrent respiratory tract infections (18/20), food allergies (14/20), oral candidiasis (12/20), bronchiectasis (11/20), asthma (8/20), autoimmunity (4/20), and non\u2010Hodgkin lymphoma (NHL) (2/20) were the most prominent clinical manifestations. Failure to thrive was present in 13 of 20 patients. Viral skin infections were less common in our series compared with the literature. Molluscum contagiosum and herpes zoster were not detected in any patient, whereas recurrent oral or labial herpes simplex infections were present in seven patients (P1, P3, P7, P11, P13, P15, and P17) and HPV in only one patient (P2).",
            "cite_spans": [],
            "section": "Patient characteristics ::: RESULTS",
            "ref_spans": [
                {
                    "start": 156,
                    "end": 157,
                    "mention": "2",
                    "ref_id": "FIGREF1"
                },
                {
                    "start": 112,
                    "end": 113,
                    "mention": "1",
                    "ref_id": "TABREF0"
                }
            ]
        },
        {
            "text": "Eighteen (90%) patients had been vaccinated with BCG prior to diagnosis. BCG\u2010itis occurred in four patients (P3, P11, P12, and P15), while disseminated BCG disease was detected in one (P6).",
            "cite_spans": [],
            "section": "Patient characteristics ::: RESULTS",
            "ref_spans": []
        },
        {
            "text": "Several hepatic problems due to infections (CMV in 4, C parvum in 1, hepatitis B in 1, and liver abscess in one patient), drug\u2010related side effects, or unknown reasons were detected in 12 of 20 patients. Cholestatic liver disease was diagnosed in two patients (P4 and P11). Agents known to cause hepatitis (hepatitis B and C viruses, CMV, and EBV) were found as negative in these patients. Cryptosporidium parvum (C parvum) was ruled out by PCR in only one patient (P11). The other patient was evaluated by acid\u2010staining test for cryptosporidium. P4 died due to cholestatic liver failure. P11 was successfully treated by liver transplantation followed by HSCT.",
            "cite_spans": [],
            "section": "Patient characteristics ::: RESULTS",
            "ref_spans": []
        },
        {
            "text": "Ten patients had chronic diarrhea, and inflammatory bowel disease (IBD) was detected in 8 of them by performing colonoscopy and biopsy. These patients were screened for gastrointestinal infectious agents with a PCR panel and with microscopy, culture, and antigen tests. Vancomycin\u2010resistant enterococci were detected in P10. Cryptosporidium parvum (C parvum) was only demonstrated in P8 by acid\u2010staining test known to have low sensitivity. Cryptosporidium was screened by acid\u2010staining test so it might have been undiagnosed in previous patients. After 2015, acid\u2010staining and PCR techniques were used together to screen the patients for C parvum.",
            "cite_spans": [],
            "section": "Patient characteristics ::: RESULTS",
            "ref_spans": []
        },
        {
            "text": "Esophageal papilloma and eosinophilic esophagitis were detected in 5 of 20 patients (P1, P6, P8, P11, and P12). All transplanted patients (P1, P8, P11, and P12) recovered.",
            "cite_spans": [],
            "section": "Patient characteristics ::: RESULTS",
            "ref_spans": []
        },
        {
            "text": "Three of DOCK8\u2010deficient patients (P5, P7, and P8) have previously been reported in the literature.8 Six novel DOCK8 mutations were detected in 17 patients and are reported for the first time (P11, P12, P14, P15/P16, P18, and P19/P20) (Table 1).",
            "cite_spans": [],
            "section": "Patient characteristics ::: RESULTS",
            "ref_spans": [
                {
                    "start": 242,
                    "end": 243,
                    "mention": "1",
                    "ref_id": "TABREF0"
                }
            ]
        },
        {
            "text": "Autoimmune hemolytic anemia was detected in three patients (P1, P9, and P11). P1 also had immune thrombocytopenia unresponsive to steroid and IVIG. Splenectomy was performed prior to HSCT. Autoimmune thyroiditis was detected in P12.",
            "cite_spans": [],
            "section": "Patient characteristics ::: RESULTS",
            "ref_spans": []
        },
        {
            "text": "In addition to previously reported data about a patient (P7),26 we detected plasmacytoma in four patients (P1, P2, P8, and P14).",
            "cite_spans": [],
            "section": "Patient characteristics ::: RESULTS",
            "ref_spans": []
        },
        {
            "text": "Three patients (P9, P10, and P12) without any history of problems at birth had pervasive developmental disorder (PDD) and speech problems. Mild cerebral atrophy was detected in P9 by cranial MRI, but MRI results were normal in other two patients.",
            "cite_spans": [],
            "section": "Patient characteristics ::: RESULTS",
            "ref_spans": []
        },
        {
            "text": "All patients had elevated serum IgE levels with a median of 2740 kU/mL (range: 358\u201036.000 kU/mL). Three patients diagnosed before the first year of life had normal peripheral blood eosinophil counts, while the other 17 patients (85%) had eosinophilia (median: 1200/mm3, range: 600\u201039300/mm3). Low serum IgM levels were detected in 15 patients (75%), CD3+ T\u2010cell lymphopenia in 10(50%), CD4+ T\u2010cell lymphopenia in 11(55%), and CD8+ T\u2010cell lymphopenia in 6 (30%). Lymphocyte activation response to PHA was found as being low in 10 patients (50%).",
            "cite_spans": [],
            "section": "Patient characteristics ::: RESULTS",
            "ref_spans": []
        },
        {
            "text": "All patients received Ig replacement therapy, trimethoprim\u2010sulfamethoxazole, acyclovir, and fluconazole prophylaxis. Severe oral herpes infection of P7 was treated successfully with interferon \u03b12b, while in P6, interferon \u03b12b treatment was ceased due to side effects (fever and myalgia) early after its initiation.",
            "cite_spans": [],
            "section": "Patient characteristics ::: RESULTS",
            "ref_spans": []
        },
        {
            "text": "A total of three patients died: two (P2 and P3) because of intracranial NHL and one (P4) because of cholestatic liver failure before the definitive DOCK8 diagnosis. Donor screening is still being processed in six patients.",
            "cite_spans": [],
            "section": "Outcome in patients who did not receive HSCT ::: RESULTS",
            "ref_spans": []
        },
        {
            "text": "Engraftment was achieved in all patients following HSCT. Median duration for engraftment of neutrophils, thrombocytes, and lymphocytes was 13 days (range: 11\u201019 days), 15 days (range: 13\u201019 days), and 15 days (range: 11\u201041 days), respectively. Full T\u2010cell chimerism (95% or more) was achieved in all patients except one (P13) who was transplanted from a haploidentical donor. P9 died due to pneumonia during the 14th month of transplantation at a local hospital although she had full donor engraftment. In transplanted patients, the median follow\u2010up time is 48 months (min\u2010max: 5\u201084 months) and overall survival rate is 91% (10/11). The data related to HSCT characteristics and outcomes are presented in Table 2.",
            "cite_spans": [],
            "section": "Outcome in patients receiving HSCT ::: RESULTS",
            "ref_spans": [
                {
                    "start": 710,
                    "end": 711,
                    "mention": "2",
                    "ref_id": "TABREF1"
                }
            ]
        },
        {
            "text": "AD and food allergies were resolved in 10 patients, and diet restrictions were ended at a median of 3 months (range: 2\u201012 months) following HSCT. Allergen\u2010specific IgE levels were also found negative in these 10 patients. No allergic reaction was detected in patients with free diet. Both the frequency and severity of infections significantly reduced in all patients. Their pulmonary function tests were improved by 45% (5/11) after transplantation. Chronic diarrhea resolved in all patients. However, growth failure did not improve after HSCT in 6 patients (P1, P5, P11, P12, P13, and P14).",
            "cite_spans": [],
            "section": "Outcome in patients receiving HSCT ::: RESULTS",
            "ref_spans": []
        },
        {
            "text": "Five patients (P3, P5, P7, P8, and P10) had active infections at the time of the transplant. Acute GvHD (Grade I\u2010III) developed in five patients (45%), and chronic GvHD developed in four (36%). Four patients who developed sinusoidal obstruction syndrome (SOS) (36%) (P1, P9, P11, and P14) had liver failure at various stages before transplantation. They all received prophylactic defibrotide treatment. All patients having SOS responded to supportive care and defibrotide treatment.",
            "cite_spans": [],
            "section": "Outcome in patients receiving HSCT ::: RESULTS",
            "ref_spans": []
        },
        {
            "text": "IVIG replacement was stopped in seven patients at a median of months (range: 6\u201014 months). One patient who was recently transplanted and three patients with cGvHD still continue to receive immunosuppressive treatment and IVIG replacement.",
            "cite_spans": [],
            "section": "Outcome in patients receiving HSCT ::: RESULTS",
            "ref_spans": []
        },
        {
            "text": "As for laboratory results, eosinophilia disappeared in all patients during the post\u2010HSCT period (median: 120/mm3, min\u2010max: 0\u2010330/mm3). Serum total IgE levels returned to normal or to near\u2010normal levels in 10 patients [post\u2010HSCT median: 40 kU/mL, min\u2010max: 2\u2010428]. Serum IgM levels were low in 8 of 11 and were normalized following transplantation in six patients. CD3+ T\u2010cell counts were low in 6 of 11 patients, and CD4+ T\u2010cell counts were low in 8 of 11 patients. After HSCT, all patients had normal CD3+ T, and CD4+ T\u2010cell counts normalized in six patients. In two siblings with Omenn phenotype (P8 and P9), CD19+ B\u2010cell levels reached normal levels after transplantation. In four patients, DOCK8 expression was examined by flow cytometry both pre\u2010 and post\u2010HSCT. All patients had a significant increase in DOCK8 expression on T cells after HSCT.",
            "cite_spans": [],
            "section": "Outcome in patients receiving HSCT ::: RESULTS",
            "ref_spans": []
        },
        {
            "text": "CD4+ CD45RA+ CD31+ T\u2010cell (RTE) counts were low in eight patients based on age\u2010specific normals at diagnosis (median: 71/mm3, min\u2010max: 42\u20101900/mm3). RTE counts did not reach age\u2010specific normal values but increased significantly (median: 179/mm3, min\u2010max: 76\u20101200/mm3). The clinical and laboratory features of the patients and outcomes related to HSCT are summarized in Table 3.",
            "cite_spans": [],
            "section": "Outcome in patients receiving HSCT ::: RESULTS",
            "ref_spans": [
                {
                    "start": 376,
                    "end": 377,
                    "mention": "3",
                    "ref_id": "TABREF2"
                }
            ]
        },
        {
            "text": "Here, we report clinical and immunologic findings of 20 DOCK8\u2010deficient patients while reviewing the outcomes of 11 transplanted cases among them. Our study is the largest single\u2010center cohort reported from Turkey. Furthermore, six novel mutations were reported in this cohort. Our patients had unique features that Turkish patients participating in previous studies did not have.8, 9 In addition to classical clinical features, gastrointestinal problems (liver and inflammatory bowel disease) were more common, while viral skin infections were less common in our series compared with the literature.8, 9 BCG vaccine\u2010related complications were seen in five patients for the first time. The median age of our patients (3 years, 2 month\u201014 years) was lower than the previous studies, and mild clinical findings were found in patients diagnosed during infancy period. Molluscum contagiosum or herpes zoster infections were not detected in our series. HPV was detected in only one patient. Mucosal herpes simplex virus (HSV) infections were observed at similar rates with the literature (35%). Gastrointestinal problems (liver and inflammatory bowel disease) in this study were more common than in previous studies.8, 9 These abovementioned differences might be due to patients\u2019 young age, the characteristics of the genetic mutations, and epigenetic factors influencing the genotype.",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "There is limited information about the speech and developmental problems in DOCK8 deficiency. Three of our patients have speech problems and pervasive developmental problems. Because all these patients\u2019 parents are consanguineous and two of the patients are siblings, it suggests that other genetic etiologies may be responsible for the PDD.",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "More than 60% of the non\u2010transplanted patients are reported to die due to malignancy or severe infections before the age of 30 years.8 In our series, three patients died before the detection of DOCK8 mutations due to central nervous NHL (P2 and P3) and liver failure (P4). Thus, HSCT is suggested to all patients with DOCK8 deficiency; even patients with significant comorbidities should undergo HSCT as early as possible after aggressive treatments of these conditions to minimize complications and to achieve engraftment.8, 9, 10, 11, 12\n",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "Recently, HSCT outcomes of 81 transplanted patients with DOCK8 deficiency from 22 centers were published. In this cohort, the median follow\u2010up time after HSCT was 26 months (3\u2010135), and 84% of the patients were alive. Survival rates were higher in the patients receiving transplants before 8 years of age and receiving RIC (treosulfan based or reduced\u2010dose busulfan) than those undergoing HSCT later than 8 years of age and receiving MAC. Of 73 patients with available chimerism data, 65 (89%) had >90% donor T\u2010cell chimerism at the last follow\u2010up.10 The outcome of HSCT even with different conditioning regimens, different GvHD prophylaxis, and different donors has been quite successful in all reported cases.10, 11, 12, 13, 14, 15, 16, 17, 18, 19, 20, 21, 22\n",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "In our study, survival rate was 91% despite the fact that most of our patients had organ damage including severe inflammatory states and half of them had active infections at the time of HSCT. MAC consisting of busulfan 4 mg/kg/day and fludarabine 40 mg/m2/day IV on days \u22125, \u22124, \u22123, and \u22122 was given to the first two patients transplanted with MRD as treosulfan could not be obtained at that time. Then, we preferred treosulfan\u2010based RIC in patients who had a high risk of developing transplant\u2010related toxicity, particularly SOS and infections. Complete chimerism was achieved in all patients except one (P13) who received RIC regimen and was transplanted from a haploidentical donor. OS was 91% in transplanted patients similar to previous studies.11, 12, 13 In our study, cGvHD rate is higher than the previous studies.10, 11, 12, 13 It could be related to severe organ damage and inflammatory morbidities due to delayed diagnosis and HSCT in our cohort. All patients who developed cGvHD were older than 4 years of age. Severe cGvHD was the most important complication we have seen after HSCT in DOCK8\u2010deficient patients.",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "Previous series report persistence of food allergies after HSCT.10, 25 However, in our series food allergies were improved in all patients except for one patient who was transplanted recently. We did not observe allergic reactions in the patients after stopping dietary restrictions.",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "Although the underlying cause of development of autoimmunity is not clear in DOCK8 deficiency, autoimmune diseases\u2014even celiac disease\u2014disappeared in our patients after transplantation.",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "Eight of 11 patients undergoing HSCT had failure to thrive. Only two patients were able to achieve normal growth after transplantation (P8 and P10). Two of the patients with growth retardation (P1 and P12) were transplanted after the age of 14. Four patients (P5, P11, P13, and P14) received long\u2010term steroid therapy for chronic GvHD treatment. P13 and P14 who were transplanted in the last two years should be monitored for their growth in the long run.",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "Clinical and laboratory findings improved in all patients after HSCT. Our results suggest that HSCT in the earliest period with MRD, MUD, or haploidentical donors, together with patient\u2010specific appropriate conditioning regimens, and GvHD prophylaxis is lifesaving for DOCK8 deficiency. cGvHD is the most important complication after HSCT. In our opinion, GvHD prophylaxis is very important and GvHD findings should be followed very closely and treated aggressively. Long\u2010term follow\u2010up is necessary to see how immunologic features progress and how effects on the prevention of malignancy and survival in transplanted patients will be.",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "Despite most of the mutations found in DOCK8\u2010deficient patients are loss\u2010of\u2010function mutations that abolish DOCK8 protein expression, very low but detectable levels of DOCK8 protein can be expressed in some patients.27 The residual DOCK8 protein contributes to the variable disease phenotype. In our cohort, four patients with mild phenotype (P15, P16, P18, and P20) diagnosed in early infancy demonstrated some residual DOCK8 protein expression by flow cytometric analysis. Therefore, examination of DOCK8 protein expression by flow cytometry in early infancy in suspected patients is a rapid and reliable diagnostic approach.",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "We suggest that all patients suspected to have DOCK8 deficiency be followed up closely, and DOCK8 expressions be measured by flow cytometry and confirmed by genetic study and performing HSCT as soon as possible.",
            "cite_spans": [],
            "section": "DISCUSSION",
            "ref_spans": []
        },
        {
            "text": "The authors declare that they have no conflicts of interest.",
            "cite_spans": [],
            "section": "CONFLICT OF INTEREST",
            "ref_spans": []
        }
    ],
    "ref_entries": {
        "TABREF0": {
            "text": "Table 1: Clinical features and outcome\n",
            "type": "table"
        },
        "TABREF1": {
            "text": "Table 2: HSCT\u2010related features, follow\u2010up, and outcome\n",
            "type": "table"
        },
        "TABREF2": {
            "text": "Table 3: Clinical and immunologic improvement in transplanted patients\n",
            "type": "table"
        },
        "FIGREF0": {
            "text": "Figure 1: DOCK8 expression by flow cytometry. DOCK8 expression of P11 pre HSCT and post HSCT",
            "type": "figure"
        },
        "FIGREF1": {
            "text": "Figure 2: Eosinophil and lymphocyte counts and serum immunoglobulin levels in DOCK8 patients. A, Counts of eosinophils (normal, 0\u2010400 cells/mL), absolute lymphocytes, and CD3+ T cells in blood. B, Counts of lymphocyte subsets. C, IgG, IgA, IgM, and total IgE levels of patients. Gray areas represent age\u2010adjusted normal ranges. Circles show high values, squares show normal values, and triangles show laboratories\u2019 lower values according to the laboratories\u2019 own normal ranges",
            "type": "figure"
        }
    },
    "back_matter": [],
    "bib_entries": {
        "BIBREF0": {
            "title": "Autosomal recessive hyperimmunoglobulin E syndrome: a distinct disease entity",
            "authors": [],
            "year": 2004,
            "venue": "J Pediatr",
            "volume": "144",
            "issn": "",
            "pages": "93-99",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF1": {
            "title": "Large deletions and point mutations involving the dedicator of cytokinesis 8 (DOCK8) in the autosomal\u2010recessive form of hyper\u2010IgE syndrome",
            "authors": [],
            "year": 2009,
            "venue": "J Allergy Clin Immunol",
            "volume": "124",
            "issn": "",
            "pages": "1289-1302",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF2": {
            "title": "Su HC Combined immunodeficiency associated with DOCK8 mutations",
            "authors": [],
            "year": 2009,
            "venue": "N Engl J Med",
            "volume": "361",
            "issn": "",
            "pages": "2046-2055",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF3": {
            "title": "Dedicator of cytokinesis 8 (DOCK8) deficiency",
            "authors": [],
            "year": 2010,
            "venue": "Curr Opin Allergy Clin Immunol",
            "volume": "10",
            "issn": "",
            "pages": "515-520",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF4": {
            "title": "DOCK8 is a Cdc42 activator critical for interstitial dendritic cell migration during immune responses",
            "authors": [],
            "year": 2012,
            "venue": "Blood",
            "volume": "119",
            "issn": "",
            "pages": "4451-4461",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF5": {
            "title": "DOCK8 functions as an adaptor that links TLRMyD88 signaling to B cell activation",
            "authors": [],
            "year": 2012,
            "venue": "Nature Immunol",
            "volume": "13",
            "issn": "",
            "pages": "612-620",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF6": {
            "title": "DOCK8 regulates signal transduction events to control immunity",
            "authors": [],
            "year": 2017,
            "venue": "Cell Mol Immunol",
            "volume": "14",
            "issn": "5",
            "pages": "406-411",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF7": {
            "title": "DOCK8 deficiency: clinical and immunological phenotype and treatment options\u2010 a review of 136 patients",
            "authors": [],
            "year": 2015,
            "venue": "J Clin Immunol",
            "volume": "35",
            "issn": "2",
            "pages": "189-198",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF8": {
            "title": "The extended clinical phenotype of 64 patients with dedicator of cytokinesis 8 deficiency",
            "authors": [],
            "year": 2015,
            "venue": "J Allergy Clin Immunol",
            "volume": "136",
            "issn": "",
            "pages": "402-412",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF9": {
            "title": "Inborn errors working party of the European group for blood and marrow transplantation and the European society for primary immunodeficiencies. Hematopoietic stem cell transplantation as treatment for patients with DOCK8 deficiency",
            "authors": [],
            "year": 2019,
            "venue": "J Allergy Clin Immunol Pract",
            "volume": "7",
            "issn": "",
            "pages": "848-855",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF10": {
            "title": "Matched related and unrelated donor hematopoietic stem cell transplantation for DOCK8 deficiency",
            "authors": [],
            "year": 2015,
            "venue": "Biol Blood Marrow Transplant",
            "volume": "21",
            "issn": "6",
            "pages": "1037-1045",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF11": {
            "title": "Hematopoietic stem cell transplantation outcomes for 11 patients with dedicator of cytokinesis 8 (DOCK8) deficiency",
            "authors": [],
            "year": 2016,
            "venue": "J Allergy Clin Immunol",
            "volume": "138",
            "issn": "3",
            "pages": "852-859",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF12": {
            "title": "Haploidentical related donor hematopoietic stem cell transplantation for dedicator of cytokinesis 8 deficiency using post transplantation cyclophosphamide",
            "authors": [],
            "year": 2017,
            "venue": "Biol Blood Marrow Transplant",
            "volume": "23",
            "issn": "6",
            "pages": "980-990",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF13": {
            "title": "Curative treatment of autosomal\u2010recessive hyper\u2010IgE syndrome by hematopoietic cell transplantation",
            "authors": [],
            "year": 2011,
            "venue": "Bone Marrow Transplant",
            "volume": "46",
            "issn": "",
            "pages": "552-556",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF14": {
            "title": "Successful long\u2010term correction of autosomal recessive hyper\u2010IgE syndrome due to DOCK8 deficiency by hematopoietic stem cell transplantation",
            "authors": [],
            "year": 2010,
            "venue": "Klin Padiatr",
            "volume": "222",
            "issn": "",
            "pages": "351-355",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF15": {
            "title": "Successful engraftment of donor marrow after allogeneic hematopoietic cell transplantation in autosomal\u2010recessive hyper\u2010IgE syndrome caused by dedicator of cytokinesis 8 deficiency",
            "authors": [],
            "year": 2010,
            "venue": "J Allergy Clin Immunol",
            "volume": "126",
            "issn": "",
            "pages": "1304-1305",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF16": {
            "title": "Successful allogeneic hematopoietic stem cell transplantation for DOCK8 deficiency",
            "authors": [],
            "year": 2011,
            "venue": "J Allergy Clin Immunol",
            "volume": "128",
            "issn": "",
            "pages": "420-422",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF17": {
            "title": "Successful bone marrow transplantation for DOCK8 deficient hyper IgE syndrome",
            "authors": [],
            "year": 2012,
            "venue": "Pediatr Transplant",
            "volume": "16",
            "issn": "",
            "pages": "398-399",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF18": {
            "title": "Clinical and immunological correction of DOCK8 deficiency by allogeneic hematopoietic stem cell transplantation following a reduced toxicity conditioning regimen",
            "authors": [],
            "year": 2012,
            "venue": "Pediatr Hematol Oncol",
            "volume": "29",
            "issn": "",
            "pages": "585-594",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF19": {
            "title": "In DOCK8 deficiency donor cell engraftment post\u2010genoidentical hematopoietic stem cell transplantation is possible without conditioning",
            "authors": [],
            "year": 2013,
            "venue": "J Allergy Clin Immunol",
            "volume": "131",
            "issn": "",
            "pages": "1244-1245",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF20": {
            "title": "Successful hematopoietic stem cell transplantation after myeloablative conditioning in three patients with dedicator of cytokinesis 8 deficiency (DOCK8) related Hyper IgE syndrome",
            "authors": [],
            "year": 2018,
            "venue": "Bone Marrow Transplant",
            "volume": "53",
            "issn": "",
            "pages": "339-343",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF21": {
            "title": "Hematopoietic stem cell transplantation from unrelated donors in children with DOCK8 deficiency",
            "authors": [],
            "year": 2017,
            "venue": "Pediatr Transplant",
            "volume": "21",
            "issn": "7",
            "pages": null,
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF22": {
            "title": "Flow cytometry diagnosis of dedicator of cytokinesis 8 (DOCK8) deficiency",
            "authors": [],
            "year": 2014,
            "venue": "J Allergy Clin Immunol",
            "volume": "134",
            "issn": "1",
            "pages": "221-223",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF23": {
            "title": "Consensus conference on acute GVHD grading",
            "authors": [],
            "year": 1995,
            "venue": "Bone Marrow Transplant",
            "volume": "15",
            "issn": "",
            "pages": "825-838",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF24": {
            "title": "National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft\u2010versus\u2010Host Disease: I. The. Diagnosis and Staging Working Group report",
            "authors": [],
            "year": 2014,
            "venue": "Biol Blood Marrow Transplant",
            "volume": "2015",
            "issn": "21",
            "pages": "389-401",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF25": {
            "title": "Plasmacytoid dendritic cell depletion in DOCK8 deficiency: rescue of severe herpetic infections with IFN\u2010\u03b1 2b therapy",
            "authors": [],
            "year": 2014,
            "venue": "J Allergy Clin Immunol",
            "volume": "133",
            "issn": "6",
            "pages": "1753-1755",
            "other_ids": {
                "DOI": []
            }
        },
        "BIBREF26": {
            "title": "Insights into immunity from clinical and basic science studies of DOCK8 immunodeficiency syndrome",
            "authors": [],
            "year": 2019,
            "venue": "Immunol Rev",
            "volume": "287",
            "issn": "",
            "pages": "9-19",
            "other_ids": {
                "DOI": []
            }
        }
    }
}